FilingReader Intelligence
Katakura subsidiary halts key drug development after trial failure
July 28, 2025 at 07:10 AM UTC•By FilingReader AI
Toa Eiyo, a Katakura Industries subsidiary, halted development of CNT-01 for triglyceride deposit cardiomyovasculopathy after Phase II/III trials showed the primary endpoint of major cardiovascular events incidence did not meet criteria.
The drug rights have been returned to Osaka University. The decision will have minor impact on Katakura's 2025 consolidated earnings.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
TSE:3001•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Katakura Industries publishes news
Free account required • Unsubscribe anytime